Details of the Drug
General Information of Drug (ID: DM4H6PC)
| Drug Name |
2-Phenethyl-4,5-dihydro-1H-imidazole
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
beta-Phenylethylimidazoline; 2-Phenethyl-2-imidazoline; 2-IMIDAZOLINE, 2-PHENETHYL-; BRN 0129593; 1H-Imidazole, 4,5-dihydro-2-(2-phenylethyl)-; 26038-62-0; 2-Phenethyl-4,5-dihydro-1H-imidazole; CHEMBL14210; 2-(beta-Phenylaethyl)imidazolin [German]; Phenyzoline; 2-(beta-Phenylaethyl)imidazolin; 2-Phenethyl-1-imidazoline; AC1L1PA8; 5-23-07-00011 (Beilstein Handbook Reference); SCHEMBL3172677; DTXSID30180682; BDBM50138499; AKOS022535828; LS-79674
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 174.24 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


